Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.35 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.34 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.34 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.34 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.34 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.34 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057031 | 1.00 | GAA (0.41) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL22100981 | 0.74 | GAA (0.44) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL16944006 | 0.71 | BRD4 (0.41) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL16944005 | 0.71 | BRD4 (0.41) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL22680884 | 0.71 | BRD4 (0.41) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL22100984 | 0.71 | BRD4 (0.41) | GAAL3MBTL1TAAR1POLBRECQL | |
| SCHEMBL301151 | 0.67 | — | — | |
| SCHEMBL16944004 | 0.63 | GAA (0.57) | GAAL3MBTL1POLBRECQLCYP2D6 | |
| SCHEMBL16944003 | 0.63 | GAA (0.57) | GAAL3MBTL1POLBRECQLCYP2D6 | |
| SCHEMBL28220353 | 0.62 | CYP2D6 (0.58) | GAAL3MBTL1TAAR1POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10517873-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190167678-A1 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | SIGNAL PHARM LLC (US) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167678-A1 | SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE | TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT | GAA 2836/4885L3MBTL1 4101/4885TAAR1 1165/4885 |
| US-10517873-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT | GAA 2836/4885L3MBTL1 4101/4885TAAR1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.